sambutoxin: produced by toxic Fusarium isolates, obtained from rotted potato tubers [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 54724817 |
| CHEBI ID | 180131 |
| MeSH ID | M0240996 |
| Synonym |
|---|
| CHEBI:180131 |
| 3-[(2s,5r,6r)-6-[(e,4r,6s)-4,6-dimethyloct-2-en-2-yl]-5-methyloxan-2-yl]-4-hydroxy-5-(4-hydroxyphenyl)-1-methylpyridin-2-one |
| 160047-56-3 |
| sambutoxin |
| (-)-sambutoxin |
| 2(1h)-pyridinone, 4-hydroxy-5-(4-hydroxyphenyl)-1-methyl-3-[(2s,5r,6r)-tetrahydro-5-methyl-6-[(1e,3r,5s)-1,3,5-trimethyl-1-hepten-1-yl]-2h-pyran-2-yl]- |
| DTXSID001100368 |
| 4-hydroxy-5-(4-hydroxyphenyl)-1-methyl-3-[(2s,5r,6r)-tetrahydro-5-methyl-6-[(1e,3r,5s)-1,3,5-trimethyl-1-hepten-1-yl]-2h-pyran-2-yl]-2(1h)-pyridinone |
| AKOS040762293 |
| FS-10439 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with sambutoxin induced the production of ROS, which caused DNA damage." | ( Discovery and Characterization of 4-Hydroxy-2-pyridone Derivative Sambutoxin as a Potent and Promising Anticancer Drug Candidate: Activity and Molecular Mechanism. Cao, ZQ; Cheng, YN; Guo, XL; Li, LN; Wang, L; Zhang, XK, 2018) | 1.06 |
| Class | Description |
|---|---|
| terpene glycoside | A terpenoid in which one or more hydroxy functions are glycosylated. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||